Results 101 to 110 of about 5,080 (193)

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve

Biomedicines
Background: Monoclonal antibodies approved by the FDA, lecanemab, donanemab, and aducanumab, are failing to meet the expected efficacy to treat early Alzheimer’s disease, and aducanumab has been recalled.
Sarfaraz K. Niazi
doaj   +1 more source

Mapping disparities in access to lecanemab in Georgia

Alzheimer's & Dementia
AbstractINTRODUCTIONThe approval of lecanemab‐irmb offers potential disease‐modifying treatments for Alzheimer's disease (AD), but geographical access barriers to infusion and amyloid positron emission tomography (PET) imaging sites might prevent timely access to the drug.
Niying Li, Samruddhi Nandkumar Borate, Kai Zhang, Mohammed Zuber, Yiran Han, Darshan Chudasama, Stephen Correia, Lisa Renzi‐Hammond   +7 more
openaire   +2 more sources

Lecanemab: A hope in the management of Alzheimer’s disease

Brain Circulation, 2023
Nandita Thakkar, Preetham Basil Martis, L V Simhachalam Kutikuppala, Sai Kiran Kuchana, Ranjan K Mohapatra   +4 more
openaire   +3 more sources

Early Outcomes of Lecanemab for Alzheimer\u2019s Disease in the Veterans Health Administration

Background/Objectives: While lecanemab (Leqembi) and several amyloid targeting therapies were approved for Alzheimer’s disease, questions remain on real-world implementation, safety, and effectiveness.
Parr, Alyssa, Timothy S. Anderson, O\u2019Donnell, Alison J., Anderson, Timothy S., Aspinall, Sherrie, Alyssa Parr, Sherrie Aspinall, Zhao, Xinhua, Alison J. O’Donnell, Xinhua Zhao   +9 more
core   +1 more source

The Alzheimer\u2019s therapeutic Lecanemab attenuates A\u3b2 pathology by inducing an amyloid-clearing program in microglia

: Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action. Here we demonstrate that Lecanemab, a leading anti-\u3b2-amyloid (A\u3b2) antibody, mediates amyloid clearance by activating microglial ...
Horr\ue9, Katrien, De Strooper, Bart, Xu, Ciana, Poovathingal, Suresh, Wolfs, Leen, Albertini, Giulia, Dewilde, Maarten, van Lieshout, Veerle, Jaspers, Tom, Snellinx, An, Cuypers, Marie-Lynn, Pasciuto, Emanuela, Fiers, Mark, Wojno, Marta, Serneels, Lurgarde, Craessaerts, Katleen, Horre, Katrien, Zielonka, Magdalena, Davie, Kristofer   +18 more
core   +1 more source

Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains

Recent advances in immunotherapeutic approaches to the treatment of Alzheimer's disease (AD) have increased the importance of understanding the exact binding preference of each amyloid-beta (A(3) antibody employed, since this determines both efficacy and
Kylefjord, Helen,, Johannesson, Malin, Zachrisson, Olof,, Svensson, Anne-Sophie,, Osswald, Gunilla,, Soderberg, Linda, Rachalski, Adeline, Rachalski, Adeline,, Nygren, Patrik,, Lannfelt, Lars, Button, Emily, Gkanatsiou, Eleni,, Svensson, Anne-Sophie, Button, Emily,, Lannfelt, Lars,, Moller, Christer, Gkanatsiou, Eleni, Nygren, Patrik, Kylefjord, Helen, Johannesson, Malin,, Osswald, Gunilla, Zachrisson, Olof, Moller, Christer,, Fritz, Nicolas, Fritz, Nicolas,, Soderberg, Linda,   +25 more
core   +1 more source

Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. [PDF]

J Clin Med
Kalampokini S, Keramidiotis I, Frontistis A, Zuchi F, Michmizos D, Papaliagkas V, Koutsouraki E.   +6 more
europepmc   +1 more source

Sabirnetug shows superior selectivity for Aβ oligomers over monomer compared to recombinant lecanemab and aducanumab

BACKGROUND: Sabirnetug (ACU193) is a monoclonal antibody designed to selectively target toxic soluble amyloid β oligomers (AβOs). Its efficacy in mild cognitive impairment (MCI) and early Alzheimer's disease (AD) is currently being investigated in the ...
Schilling, Stephan, Cline, Erika N., Johnson, Elizabeth, Schenk, Mathias, Kleinschmidt, Martin, Lavoie, Thomas, Rahfeld, Jens-Ulrich, Jerecìć, Jasna   +7 more
core   +1 more source

Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181. [PDF]

J Prev Alzheimers Dis
Noguchi-Shinohara M, Muramatsu D, Shima A, Sakashita Y, Tada Y, Yamaguchi H, Komatsu J, Ikeda T, Ono K.   +8 more
europepmc   +1 more source

Unblinding in the lecanemab trial in Alzheimer’s disease

Brain, 2023
openaire   +2 more sources